Table 1 Patient characteristics
Characteristics | Training dataset (n = 88) | Validation dataset (n = 38) | P-value |
|---|---|---|---|
Sex | 0.134 | ||
Male | 69 (78.4) | 25 (65.8) | |
Female | 19 (21.6) | 13 (34.2) | |
Age (years) | 43.3 ± 9.1 | 46.0 ± 9.2 | 0.128 |
Overall stage | 0.639 | ||
III | 48 (54.5) | 19 (50.0) | |
IV | 40 (45.5) | 19 (50.0) | |
Histology, WHO Type | 0.275 | ||
I | 2 (2.3) | 0 | |
II | 28 (31.8) | 17 (44.7) | |
III | 58 (65.9) | 21 (55.3) | |
EBV-DNA (copies/mL) | 0.585 | ||
≤400 | 46 (52.3) | 18 (47.4) | |
>400 | 26 (29.5) | 10 (26.3) | |
Unknown | 16 (18.2) | 10 (26.3) | |
IC regimens | 0.853 | ||
TP | 19 (21.6) | 8 (21.1) | |
DP | 19 (21.6) | 10 (26.3) | |
DPF | 45 (51.1) | 19 (50.0) | |
TPF | 5 (5.7) | 1 (2.6) | |
IC cycles | 0.880 | ||
2 | 52 (59.1) | 23 (60.5) | |
3 | 36 (40.9) | 15 (39.5) | |
Treatment response | 0.287 | ||
Responder | 75 (85.2) | 35 (92.1) | |
Non-responder | 13 (14.8) | 3 (7.9) | |
Median PFS (months) | 49.1 (41.4, 58.7) | 48.8 (41.9, 54.7) | 0.776 |